Luigi Mangione to plead guilty in murder of UnitedHealthcare CEO Brian Thompson

Luigi Mangione is expected to plead guilty to federal charges linked to the 2024 murder of UnitedHealthcare chief executive Brian Thompson in Manhattan, NBC News reports. Prosecutors say Mangione, a 38‑year‑old former employee of a rival health‑insurance firm, is charged with murder, conspiracy to commit murder and other related offenses. The plea is anticipated in the coming weeks at the U.S. District Court for the Southern District of New York, where the case is being prosecuted under federal jurisdiction.

Thompson was found dead in his Manhattan office on February 12, 2024, after a sudden heart attack was ruled out. Investigators linked the killing to a dispute over a lucrative contract that UnitedHealthcare had secured with a major hospital system. Mangione allegedly threatened Thompson with a weapon in a private meeting, and witnesses say he fled the scene before police arrived. The case drew national attention because UnitedHealthcare is one of the largest health‑insurance providers in the United States, and the murder occurred in a high‑profile corporate setting.

Under federal sentencing guidelines, Mangione could face up to 20 years in prison if he pleads guilty to first‑degree murder. Prosecutors have indicated that a plea deal might reduce the sentence if he cooperates with investigators. Misty Marris, a legal analyst for NBC News, notes that Mangione could also face charges of conspiracy to commit murder and possession of a weapon in a federal facility, each carrying additional years. The defense has not yet announced its strategy, but a guilty plea would likely prevent a jury trial and the risk of a death sentence, which is not available in federal courts.

UnitedHealthcare issued a statement saying it was "devastated" by the loss of Thompson and that it would support the legal process. The company also announced a review of its security protocols. The plea hearing is scheduled for March 15, after which a sentencing date will be set. The outcome will be closely watched, as it could set a precedent for how federal courts handle corporate homicide cases involving high‑profile executives.